Patient safety challenges in treprostinil therapy.
Treprostinil (Remodulin) is a new therapy for pulmonary hypertension. A multidisciplinary plan for safely managing the drug is described, and includes a flow chart to guide practice through high-risk issues.
University Medical Center, Tucson, AZ, USA.
Agnes
A
Roncesvalles
Fu Wen
FW
Lee
James
J
Camamo
Gail
G
Priestley
D000046:Academic Medical Centers; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016903:Drug Monitoring / Q000379:methods / Q000451:nursing; D011464:Epoprostenol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004867:Equipment Design; D004868:Equipment Failure; D006801:Humans; D006976:Hypertension, Pulmonary / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy*; D007260:Infusion Pumps / Q000600:supply & distribution; D007262:Infusions, Intravenous; D009730:Nursing Assessment; D009737:Nursing Records; D010347:Patient Care Planning / Q000458:organization & administration; D010348:Patient Care Team / Q000458:organization & administration*; D010353:Patient Education as Topic; D017751:Safety Management / Q000458:organization & administration*; D012720:Severity of Illness Index; D015206:Southwestern United States; D017749:Total Quality Management / Q000458:organization & administration*
D000959:Antihypertensive Agents; D011464:Epoprostenol; C427248:treprostinil